Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin

AIM: Eribulin mesylate is a non-taxane microtubule dynamics inhibitor that was recently approved for treatment of metastatic breast cancer. The aim of this study was to determine the effect of rifampicin, a CYP3A4 inducer, on the plasma pharmacokinetics of eribulin in patients with solid tumours. ME...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Devriese, Lot A, Witteveen, Petronella (Els) O, Wanders, Jantien, Law, Kenneth, Edwards, Geoff, Reyderman, Larisa, Copalu, William, Peng, Fuping, Marchetti, Serena, Beijnen, Jos H, Huitema, Alwin D R, Voest, Emile E, Schellens, Jan H M
פורמט: Artigo
שפה:Inglês
יצא לאור: Blackwell Science Inc 2013
נושאים:
Drug Interactions
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3579265/
https://ncbi.nlm.nih.gov/pubmed/22803519
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2012.04381.x
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים